Breaking News

Norwich Names Pharma Development VP

January 17, 2013

Arnold to lead product development and technical services

Kristin Arnold, Ph.D. has been appointed vice president of product development and technical services (PDTS) at Norwich Pharmaceuticals. Dr. Arnold will provide strategic leadership for the PDTS group that includes R&D, GMP pilot scale manufacturing, analytical development and validation, and testing services. She reports to chief executive officer, Doug Drysdale.
 
Prior to joining the company, Dr. Arnold held positions with URL Pharma as senior vice president of Product Development, Alpharma as senior director R&D, FMC Corp., Ecogen, and Monsanto.
 
"We are pleased to welcome Kristin Arnold to Norwich and look forward to her contributions to the PDTS group and the organization," said Mr. Drysdale. "Her expertise in product development from product conception through market launch will be an advantage for our customers and she will be a strong addition to our leadership team."

Related Compliance:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks